<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244723</url>
  </required_header>
  <id_info>
    <org_study_id>VPLUS</org_study_id>
    <nct_id>NCT02244723</nct_id>
  </id_info>
  <brief_title>Diagnostic Value of Lung Ultrasound for Ventilator-Associated Pneumonia</brief_title>
  <acronym>VPLUS</acronym>
  <official_title>Prospective, Observational Study of Diagnostic Value of Lung Ultrasound for Ventilator-Associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventilator-associated pneumonia (VAP) is the most common nosocomial infection acquired by&#xD;
      mechanically-ventilated patients in the intensive care unit (ICU). It has significant&#xD;
      clinical and economic consequences, as it is associated with considerable morbidity,&#xD;
      increased mortality, and excess health care costs. Appropriate antibiotic therapy for&#xD;
      patients with VAP significantly improves outcomes, making rapid identification of patients&#xD;
      with VAP an important clinical goal.&#xD;
&#xD;
      This application is for support of a prospective, multi-centered study to evaluate the&#xD;
      diagnostic value of lung ultrasound for VAP. The primary hypothesis is that the association&#xD;
      of the Clinical Pulmonary Infection Score (CPIS) to specific lung ultrasound signs could&#xD;
      allow for early and reliable diagnosis of bacterial VAP.&#xD;
&#xD;
      Objective 1: To evaluate the sensitivity, specificity, and diagnostic accuracy of lung&#xD;
      ultrasound alone and in association with the CPIS.&#xD;
&#xD;
      Objective 2: To determine the frequency of specific lung ultrasound signs (subpleural&#xD;
      consolidation, irregular B-lines) in VAP.&#xD;
&#xD;
      Objective 3: To promote development of a diagnostic pathway for VAP incorporating CPIS, lung&#xD;
      ultrasound, and unprotected tracheal aspirate (UTA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled within 24 hours of the point at which criteria are met for&#xD;
      suspected VAP. Upon enrollment, the following variables will be recorded from the online&#xD;
      medical record, and a Clinical Pulmonary Infection Score will be calculated.&#xD;
&#xD;
        -  Demographics (height, weight, comorbidities)&#xD;
&#xD;
        -  Ventilation parameters&#xD;
&#xD;
        -  Infectious disease data during present admission (antibiotic history, culture data)&#xD;
&#xD;
        -  Biochemical data (WBC count with differential, arterial blood gas)&#xD;
&#xD;
        -  Microbiological data (UTA and BAL) - UTA data must have been collected within 24 hours&#xD;
           of enrollment and BAL data within 12 hours of enrollment&#xD;
&#xD;
        -  Radiological data (CXR or chest CT)&#xD;
&#xD;
      Lung ultrasound will be performed within 24 hours of the point at which criteria are met for&#xD;
      suspected VAP. Lung ultrasound will include examination of both lungs. Each hemithorax will&#xD;
      be divided into three regions using anterior and posterior axillary lines as landmarks. Each&#xD;
      of these regions will be further divided into upper and lower quadrants, yielding a total of&#xD;
      6 quadrants per hemithorax. Examination will specifically identify the presence or absence of&#xD;
      the following lung ultrasound findings: normal pleural A lines, non-coalescent B lines,&#xD;
      coalescent B lines, consolidations (subpleural or lobar), and linear air bronchograms. A Lung&#xD;
      Ultrasound Aeration Score will be calculated based on these findings. Ultrasonographic&#xD;
      diagnosis of VAP will be defined based on the presence of subpleural consolidation, entire&#xD;
      lobar consolidation, or air bronchogram within consolidation.&#xD;
&#xD;
      The results of microbiological data will be followed up for confirmation of culture results.&#xD;
      Cultures will be considered positive if ≥ 100,000 bacterial colony-forming units (cfu) are&#xD;
      isolated.&#xD;
&#xD;
      At day #28 of study enrollment, the patient's status will be documented (alive vs. deceased,&#xD;
      inpatient vs. discharged).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2013</start_date>
  <completion_date type="Actual">September 1, 2015</completion_date>
  <primary_completion_date type="Actual">January 1, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ventilator-associated pneumonia.</measure>
    <time_frame>up to 30days</time_frame>
    <description>Ventilator associated pneumonia is diagnosed when patient has a positive broncho alveolar lavage (positive cultiure &gt;10*3 CFU/ml) and clinical criteria (◦Body temperature ≥ 38.5° C (101° F) or &lt; 36° C (97° F)&#xD;
White blood cell count &gt; 10,000/ml or &lt; 4,000/ml or &gt; 10% immature cells&#xD;
Partial pressure of oxygen in arterial blood &lt; 60 mmHg or partial pressure of oxygen in arterial blood/ inspired oxygen fraction ratio &lt; 300&#xD;
Purulent respiratory secretion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in ICU</measure>
    <time_frame>up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital say</measure>
    <time_frame>up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, and diagnostic accuracy of lung ultrasound to diagnose ventilator-associated pneumonia</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensitivity, specificity, and diagnostic accuracy of lung ultrasound in association with the CPIS to diagnose ventilator-associated pneumonia</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensitivity, specificity, and diagnostic accuracy of lung ultrasound in association with unprotected tracheal aspirate to diagnose ventilator-associated pneumonia</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">98</enrollment>
  <condition>Ventilator-Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Patients with suspected VAP</arm_group_label>
    <description>Only one group is studied : mechanically-ventilated patients with suspected VAP in ICUs.&#xD;
For each patient a lung ultrasound examination will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lung ultrasound examination</intervention_name>
    <description>Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia</description>
    <arm_group_label>Patients with suspected VAP</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Biochemical data (WBC count with differential, arterial blood gas)&#xD;
&#xD;
        -  Microbiological data (UTA and BAL) - UTA data must have been collected within 24 hours&#xD;
           of enrollment and BAL data within 12 hours of enrollment (unprotected tracheal aspirate&#xD;
           (UTA)- fibrobronchoscopy with protected distal sampling)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        subjects will be recruited from mechanically-ventilated patients with suspected VAP in ICUs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mechanical ventilation for at least 48 hours,&#xD;
&#xD;
          -  New or evolving infiltrate on chest radiograph (CXR) or computed tomography (CT), and&#xD;
&#xD;
          -  A minimum of two of the following clinical criteria:&#xD;
&#xD;
               -  Body temperature ≥ 38.5° C (101° F) or &lt; 36° C (97° F)&#xD;
&#xD;
               -  White blood cell count &gt; 10,000/ml or &lt; 4,000/ml or &gt; 10% immature cells&#xD;
&#xD;
               -  Partial pressure of oxygen in arterial blood &lt; 60 mmHg or partial pressure of&#xD;
                  oxygen in arterial blood/ inspired oxygen fraction ratio &lt; 300&#xD;
&#xD;
               -  Purulent respiratory secretions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Known ongoing pneumonia&#xD;
&#xD;
          -  Patient younger than 18 years old&#xD;
&#xD;
          -  Mechanical ventilation &lt;48 hours&#xD;
&#xD;
          -  Contraindication to bronchoscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>GH Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rianimazione I, (Dipartement of Anesthesia and Intensive Care Unit) of Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bouhemad B, Liu ZH, Arbelot C, Zhang M, Ferarri F, Le-Guen M, Girard M, Lu Q, Rouby JJ. Ultrasound assessment of antibiotic-induced pulmonary reaeration in ventilator-associated pneumonia. Crit Care Med. 2010 Jan;38(1):84-92. doi: 10.1097/CCM.0b013e3181b08cdb.</citation>
    <PMID>19633538</PMID>
  </reference>
  <reference>
    <citation>Bouhemad B, Brisson H, Le-Guen M, Arbelot C, Lu Q, Rouby JJ. Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med. 2011 Feb 1;183(3):341-7. doi: 10.1164/rccm.201003-0369OC. Epub 2010 Sep 17.</citation>
    <PMID>20851923</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Paris Saint Joseph</investigator_affiliation>
    <investigator_full_name>bélaid BOUHEMAD</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Ventilator-Associated Pneumonia</keyword>
  <keyword>diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

